Landmark Publication Further Validates Approach to Expand the Potential Universe of Cancer-specific Targets by Probing the “Grey Genome”
Results provide foundational proof-of-concept for a unique target ID in glioblastoma, build further confidence in Mnemo’s EnfiniT Discovery Engine PARIS, June 9, 2022 — Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies,…